- Home
- MYGN vs GHLD Comparison
MYGN vs GHLD Comparison
Compare MYGN & GHLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- GHLD
- Stock Information
- Founded
- MYGN 1991
- GHLD 1960
- Country
- MYGN United States
- GHLD United States
- Employees
- MYGN N/A
- GHLD N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- GHLD Finance: Consumer Services
- Sector
- MYGN Health Care
- GHLD Finance
- Exchange
- MYGN Nasdaq
- GHLD Nasdaq
- Market Cap
- MYGN 744.7M
- GHLD 806.4M
- IPO Year
- MYGN 1995
- GHLD 2020
- Fundamental
- Price
- MYGN $4.13
- GHLD $12.92
- Analyst Decision
- MYGN Hold
- GHLD Buy
- Analyst Count
- MYGN 16
- GHLD 5
- Target Price
- MYGN $16.40
- GHLD $16.30
- AVG Volume (30 Days)
- MYGN 3.4M
- GHLD 9.5K
- Earning Date
- MYGN 05-06-2025
- GHLD 05-07-2025
- Dividend Yield
- MYGN N/A
- GHLD 3.89%
- EPS Growth
- MYGN N/A
- GHLD 63.18
- EPS
- MYGN N/A
- GHLD 0.71
- Revenue
- MYGN $831,300,000.00
- GHLD $1,131,796,000.00
- Revenue This Year
- MYGN N/A
- GHLD $5.99
- Revenue Next Year
- MYGN $7.21
- GHLD $24.90
- P/E Ratio
- MYGN N/A
- GHLD $18.06
- Revenue Growth
- MYGN 7.38
- GHLD 32.57
- 52 Week Low
- MYGN $3.98
- GHLD $11.21
- 52 Week High
- MYGN $29.30
- GHLD $18.26
- Technical
- Relative Strength Index (RSI)
- MYGN 25.47
- GHLD 48.87
- Support Level
- MYGN $3.81
- GHLD $11.99
- Resistance Level
- MYGN $4.31
- GHLD $13.68
- Average True Range (ATR)
- MYGN 0.47
- GHLD 0.59
- MACD
- MYGN -0.16
- GHLD 0.00
- Stochastic Oscillator
- MYGN 8.00
- GHLD 51.38
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About GHLD Guild Holdings Company
Guild Holdings Co is a growth-oriented mortgage company. It operates in two segments; The origination segment operates its loan origination business throughout the United States. It is responsible for loan origination, acquisition, and sale activities. This segment is further divided into retail and correspondent channel, and The servicing segment provides a steady stream of cash flow to support the origination segment more importantly it allows for the Company to build long-standing client relationships that drive repeat and referral business back to the origination segment to recapture the client's next mortgage transaction. It is responsible for the servicing activities of all loans in its servicing portfolio. It generates a majority of its revenue from the Origination segment.